Duration of antidepressant use during pregnancy and risk of major congenital malformations
- 1 May 2008
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 192 (5), 344-350
- https://doi.org/10.1192/bjp.bp.107.042523
Abstract
Background: Antidepressant use during the gestational period is a controversial topic.Aims: To determine whether duration of antidepressant use during the first trimester increases the risk of major congenital malformations in offspring of women diagnosed with psychiatric disorders.Method: A case-control study was performed among women who had been pregnant between January 1998 and December 2002. Data were obtained from a Medication and Pregnancy registry, built by linking three databases from the province of Quebec, and a self-administered questionnaire. Women eligible for this study had to be 15–45 years old at the beginning of pregnancy, have at least one diagnosis of psychiatric disorder before pregnancy, have used antidepressants for ≥ 30 days in the year prior to pregnancy and have a pregnancy ending with a delivery. Cases were defined as any major congenital malformation diagnosed in the offspring's first year of life. Odds ratios, adjusted for relevant confounders, were estimated using logistic regression.Results: Among the 2329 women meeting the inclusion criteria, 189 (8.1%) infants were born with a major congenital malformation. Duration of antidepressant use during the first trimester of pregnancy was not associated with an increased risk of major congenital malformations: 1–30 days v. 0 day, adjusted OR=1.23 (95% CI 0.77–1.98); 31–60 days v. 0 day, adjusted OR=1.03 (95% CI 0.63–1.69); ≥ 61 days v. 0 day, adjusted OR=0.92 (95% CI 0.50–1.69).Conclusions: These data do not support an association between duration of antidepressant use during the first trimester of pregnancy and major congenital malformations in the offspring of women with psychiatric disorders. These findings should help clinicians decide whether to continue antidepressant therapy during pregnancy.Keywords
This publication has 31 references indexed in Scilit:
- Use of Selective Serotonin-Reuptake Inhibitors in Pregnancy and the Risk of Birth DefectsNew England Journal of Medicine, 2007
- First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosageBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2006
- Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the NewbornNew England Journal of Medicine, 2006
- The Safety of Newer Antidepressants in Pregnancy and BreastfeedingDrug Safety, 2005
- Eating disorders: recognition, evaluation, and implications for obstetrician/gynecologistsPrimary Care Update for OB/GYNS, 2001
- Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: Pharmacist and mother as sources for drug exposure data during pregnancyTeratology, 1999
- Birth Outcomes in Pregnant Women Taking FluoxetineNew England Journal of Medicine, 1996
- Maternal Depressive Symptoms and the Risk of Poor Pregnancy OutcomeEpidemiologic Reviews, 1995
- Better news on populationThe Lancet, 1992
- Depressive symptoms during pregnancy: Relationship to poor health behaviorsAmerican Journal of Obstetrics and Gynecology, 1989